Adium pharma s.a registration#

PharmaMar has a pipeline of drug candidates and a robust R&D oncology program.

Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity.

Adium pharma s.a registration#

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction. We rely on ADIUM's capabilities and infrastructure to maximize access to trabectedin to all patients with sarcoma or ovarian cancer'. Former product licensee Janssen will continue to commercialize the product in this territory, until its marketing authorizations are formally transferred to ADIUM.Īccording to Luis Mora, Managing Director of PharmaMar’s Oncology Business Unit, 'We are pleased to have partnered Yondelis® with ADIUM for the Latin American market with more than 20 countries. Through this new alliance, ADIUM will also pursue additional regulatory approvals, as well as public price approval where not yet conceded. Trabectedin is currently provided by Janssen to patients in most of Latin American countries, for the treatment of soft tissue sarcoma and relapsed ovarian cancer. This new agreement follows PharmaMar's announcement on August 26th, 2019, regarding the agreement entered into with Janssen Products LP (Janssen), by which PharmaMar recovered the commercialization rights of the product in more than 40 countries, formerly licensed to Janssen, where trabectedin has already been approved. PharmaMar will retain exclusive production rights of the product and will sell the product to ADIUM for its clinical and commercial use. Under the terms of the agreement, PharmaMar will receive a non-disclosed upfront payment and will be eligible for additional remunerations, including regulatory milestone payments. to commercialize the marine-derived anticancer drug Yondelis® (trabectedin) in Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Curacao, Dominican Republic, Ecuador, El Salvador, Guatemala, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Trinidad and Tobago, Uruguay and Venezuela. – PharmaMar (MSE:PHM) has announced today a licensing agreement with ADIUM Pharma S.A. The team excels at complex cross-border transactions involving Bermuda, British Virgin Islands, Cayman Islands, Cyprus and Luxembourg vehicles.Madrid, July 27th, 2020. The team of corporate and finance lawyers at Harneys have strong networks with industry players and service providers in key markets around the world and understand the business environment in which their clients operate. The Adium group operates one of the leading pharmaceutical businesses in Latin America, with presence in 17 countries across the region and a track record of over 40 years, dedicated to the manufacturing, packaging, distribution, and commercialization of pharmaceutical products. Mitrani, Caballero & Ruiz Moreno acted as instructing law firm. The Harneys team was led by Partner Josh Mangeot, with support from Associate Ed Lacey. by a consortium of lenders, including Banco Itaú Uruguay S.A., which also acted as sole lead arranger and book runner.

in relation to the US$130 million term loan financing of its subsidiary Adium Pharma S.A. Harneys acted as BVI counsel to Adium Ltd.